论文部分内容阅读
我院于1979~1991年收治经初治获得完全缓解而复发的儿童非何杰金氏淋巴瘤71例,均经病理证实。分期:Ⅰ期2例,Ⅱ期40例,Ⅲ期14例,Ⅳ期15例。71例中68例给予COCP/CHOP交替化疗4~8周期,3例沿用初治方案COCP化疗4周期。结果:CR34例,占47.9%,PR22例,占31.0%,有效率为78.9%,1、3、5年生存率分别为53.5%、26.8%、21.1%,再化疗疗效较好。本文且按复发时间、近期缓解度、部分临床特点分组进行了1、3、5年生存率的对比,结果表明:1年内复发患者组1、3、5年生存率分别低于1年后复发者(P<0.05);经再化疗获得CR组分别高于未获得CR组(P<0.05);无B症状组分别高于伴B症状组,但经统计学处理,P值分别>0.05。作者认为对复发性NHL患者的治疗,应趋向于多种互不交叉耐药的化疗方案交替治疗,争取获得CR,提高生存率。
In our hospital from 1979 to 1991, 71 children with non-Hodgkin’s lymphoma who had been completely relieved and relapsed after initial treatment were confirmed by pathology. Staging: Ⅰ in 2 cases, Ⅱ in 40 cases, Ⅲ in 14 cases, Ⅳ in 15 cases. In 71 cases, 68 cases were given COCP / CHOP alternating chemotherapy for 4 to 8 cycles, and 3 patients were treated with the initial regimen COCP chemotherapy for 4 cycles. Results: CR34 cases, accounting for 47.9%, PR22 cases, accounting for 31.0%, the effective rate was 78.9%, 1,3,5-year survival rates were 53.5%, 26.8%, 21 respectively. 1%, then the better effect of chemotherapy. According to the recurrence time, recent remission, and some clinical features, the 1, 3 and 5-year survival rates were compared between groups. The results showed that the 1,3 and 5-year survival rates of recurrence patients within 1 year were less than 1 year respectively (P <0.05). The CR rates in re-treatment group were higher than those in CR group (P <0.05), those in non-B group were higher than those in B group 0.05. The authors believe that the treatment of recurrent NHL patients should tend to a variety of non-cross-resistant chemotherapy regimens alternately treatment for CR, improve survival.